Raymond James Trust N.A. Viking Therapeutics, Inc. Transaction History
Raymond James Trust N.A.
- $4.55 Billion
- Q3 2024
A detailed history of Raymond James Trust N.A. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Trust N.A. holds 4,410 shares of VKTX stock, worth $217,016. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,410Holding current value
$217,016% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
474Shares Held
66.2MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$500 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$297 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$230 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$104 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$92.3 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.77B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...